Lithium Monotherapy Increases ACTH and Cortisol Response in the Dex/CRH Test in Unipolar Depressed Subjects. A Study with 30 Treatment-Naive Patients
Lithium Monotherapy Increases ACTH and Cortisol Response in the Dex/CRH Test in Unipolar Depressed Subjects. A Study with 30 Treatment-Naive Patients
复制标题
DOI：
10.1371/journal.pone.0027613
复制
发表时间：
2011-11-23
期刊：
影响因子：
3.7
通讯作者：
Lewitzka, Ute
中科院分区：
文献类型：
--
作者：
Bschor, Tom;Ritter, Dirk;Lewitzka, Ute
背景资料：下丘脑-垂体-肾上腺皮质（HPA）系统的异常活动是抑郁症最有力的生物学异常之一。锂是治疗情感性精神障碍的重要药物，但其对抑郁症患者HPA系统的影响尚不清楚。目的：通过DEX/CRH联合试验，评价锂单药治疗对抑郁症患者HPA系统的影响。（单次发作或单极复发; SCID I和II证实）用锂单药治疗四周。DEX/CRH测试在摄入第一片锂片之前和之后四周进行。HDRS 21每周评分用于确定反应（>= 50%症状减轻）和缓解（HDRS
Background: Distorted activity of the hypothalamic-pituitary-adrenocortical (HPA) system is one of the most robustly documented biological abnormalities in major depression. Lithium is central to the treatment of affective disorders, but little is known about its effects on the HPA system of depressed subjects.Objective: To assess the effects of lithium monotherapy on the HPA system of patients with major depression by means of the combined DEX/CRH test.Method: Thirty drug-naive outpatients with major depression (single episode or unipolar recurrent; SCID I-and II-confirmed) were treated with lithium monotherapy for four weeks. The DEX/CRH test was conducted directly before intake of the first lithium tablet and four weeks thereafter. Weekly ratings with the HDRS21 were used to determine response (>= 50% symptom reduction) and remission (HDRS